Welcome to our dedicated page for SenesTech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
Glenbrook Capital Management, a Nevada-based investment manager, reports beneficial ownership of 1,057,804 shares of SenesTech common stock, representing 19.95% of the 5,303,426 shares outstanding as of May 11, 2026.
Glenbrook acquired the position for approximately $3.6 million from its working capital through funds and managed accounts, viewing SenesTech as undervalued and an attractive investment. It also holds warrants in PFS Trust and an employee profit-sharing plan that are subject to 9.99% and 4.99% beneficial ownership blockers, limiting further exercises.
The firm characterizes the holding as an investment but has been, and may continue to be, actively engaged with SenesTech’s management, board and other shareholders on strategy, operations, marketing, capital structure and governance, and may increase or decrease its economic exposure over time.
Glenbrook Capital Management, a ten percent owner of SenesTech, Inc., reported purchasing 35,000 shares of common stock on July 20, 2026 at an average price of $1.4734 per share in an open-market or private transaction. Following this trade, an account it manages held 1,057,824 shares indirectly. Glenbrook states these securities are held for a managed account and it disclaims beneficial ownership except to the extent of its pecuniary interest. The transaction was not marked as being under a Rule 10b5-1 trading plan.
SenesTech, Inc. Chief Executive Officer Michael Edell reported an open-market purchase of 1,000 shares of Common Stock at about $1.43 per share. This buy increased his direct holdings to 5,000 shares, indicating a larger personal stake in the company’s equity.
SenesTech, Inc. reported an insider transaction involving an account managed by Glenbrook Capital Management, a ten percent owner. On June 30, 2026, the account made an open-market purchase of 35,000 shares of common stock at an average price of $1.5066 per share. Following this trade, the account indirectly holds 1,022,824 shares of SenesTech common stock. Glenbrook Capital Management serves as investment manager to the account and disclaims beneficial ownership of these securities except to the extent of its pecuniary interest, if any.
SenesTech, Inc. reported that an account managed by Glenbrook Capital Management made a series of open-market purchases of its common stock. Between June 24 and June 29, 2026, the account bought a total of 25,416 shares at prices around $1.52–$1.56 per share. After these transactions, the account held 987,824 shares of SenesTech common stock indirectly. Glenbrook Capital Management is investment manager to the account and disclaims beneficial ownership of these securities except to the extent of its pecuniary interest.
SenesTech, Inc. reported that Glenbrook Capital Management, as investment manager for an account it oversees, made two open-market purchases of SenesTech common stock. The account bought 3,264 shares at $1.6139 per share on June 17, 2026 and 5,000 shares at $1.6591 per share on June 22, 2026, for a total of 8,264 shares purchased. Following these transactions, the account held 962,408 shares of SenesTech common stock indirectly. Glenbrook Capital Management disclaims beneficial ownership of these securities for Section 16 purposes except to the extent of any pecuniary interest.
SenesTech, Inc. director Joshua Matthew Moss received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $1.65 per share, expire on June 15, 2036, and vest in 12 equal monthly installments over one year. Following this award, Moss holds derivative options on 100,000 shares directly.
SenesTech, Inc. director Phillip Nicholas Grandinetti III received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $1.65 per share, become exercisable over one year in 12 equal monthly installments, and expire on June 15, 2036. Following this award, he holds stock options for 100,000 shares directly.
SenesTech, Inc. director Jacob Steven Leach received a stock option grant covering 100,000 shares of common stock. The option has an exercise price of $1.65 per share, was granted on June 15, 2026, and expires on June 15, 2036.
The award vests monthly over one year in 12 equal installments, starting after the grant date. Following this grant, Leach holds derivative rights to acquire 100,000 shares through this option, reflecting a compensation-related equity incentive rather than an open-market purchase or sale.
SenesTech, Inc. director Matthew K. Szot received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $1.6500 per share, were granted at no cost, and vest in 12 equal monthly installments over one year. The options expire on June 15, 2036, and following this grant Szot holds 100,000 options directly as compensation rather than through any open-market purchase.